NS005

NS005 is a preclinical-stage drug candidate being developed by Nasus Pharma for the treatment of cardiovascular disorders. It utilizes Nasus Pharma's proprietary powder-based intranasal (PBI) technology platform, which is designed to facilitate rapid drug absorption through the nasal mucosa. Although earlier reports from 2025 linked the NS005 designation to an intranasal midazolam powder for acute seizures, current company pipeline data as of March 2026 identifies the program as targeting cardiovascular diseases. The specific active pharmaceutical ingredient and biological target for this indication have not yet been disclosed.